Search

Your search keyword '"Paustian, Christopher"' showing total 87 results

Search Constraints

Start Over You searched for: Author "Paustian, Christopher" Remove constraint Author: "Paustian, Christopher"
87 results on '"Paustian, Christopher"'

Search Results

1. 680 Multi-parametric assessment of the immune response to a trio immunotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma

3. Abstract CT123: Trial in progress: First-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma

4. Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer

5. 5 Development of a vaccine to intercept oral cancer

6. Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study

7. Abstract CT502: Preliminary immunological monitoring of first-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma

8. Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study.

12. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer

13. 443 An immunotherapy trio in advanced HNSCC for coordinated B and T cell antigen response

14. 480 Preliminary evaluation of a novel coronavirus vaccine (CORVax) using electroporation of plasmid DNA encoding a stabilized prefusion SARS-CoV-2 spike protein alone or with transfection of plasmid IL-12

16. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

17. A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer

18. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

19. Abstract 38: Development of a DC-targeted microvesicle vaccine to intercept the progression of oral preneoplasia to cancer

20. T cell population expansion in response to allogeneic cancer vaccine alone (DPV-001) or with granulocyte-macrophage colony-stimulating factor (GM-CSF) or imiquimod (I) for definitively-treated stage III NSCLC patients (pts).

21. P2.02-043 Randomized Ph II Trial of Allogeneic DPV-001 Cancer Vaccine Alone or with Adjuvant for Curatively-Treated Stage III NSCLC

22. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

23. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

24. Abstract CT053: Intratumoral coxsackievirus A21 increases immune-cell infiltrates and upregulates immune-checkpoint molecules in the tumor microenvironment of advanced melanoma patients: phase II CALM extension study

25. Dynamics of tumor response in advanced melanoma patients treated with Coxsackievirus A21.

26. Adoptive TIL in HPV-negative oral scca

28. Recurrence of head and neck squamous cell cancer following resection may be predicted by assessment of immune infiltrates within the tumor (TUM10P.1056)

29. Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC

31. Evaluation of circulating tumor cell gene expression profiles before and following combination immunotherapy for advanced prostate cancer

32. Utilizing quantitative immunohistochemistry for relationship analysis of tumor microenvironment of head and neck cancer patients

33. Characterizing the immunoprofile and endogenous immune response to squamous cell carcinomas of the head and neck to guide development of effective immunotherapy strategies

34. Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC

36. Developing an immunotherapy strategy for the effective treatment of patients with squamous cell carcinoma of the head and neck

45. Cross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory t cells.

46. STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34poscells into tumor-competent dendritic cells

47. Additional file 1: Table S1. of A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer

49. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

50. Additional file 1: Table S1. of A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer

Catalog

Books, media, physical & digital resources